Literature DB >> 32322681

Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients.

Phillip Olla1, Mohd Tazim Ishraque1, Stephen Bartol2.   

Abstract

The legalization of cannabis in Canada brings novel challenges across various fronts, such as policy development, law enforcement, and public health and safety. It is imperative to improve our understanding of the mechanisms and trends surrounding cannabis use to develop efficacious methods of tackling these challenges. Materials and
Methods: Patients' breath collection was achieved using the ExaBreath device from SensAbues. THC measurements in plasma and breath samples were processed and analyzed using LC-MS/MS. Discussion: We conducted a pragmatic clinical trial on 23 medical cannabis patients, wherein we collected breath and plasma samples intermittently for 4 hours after cannabis consumption. The research participants consumed between 1 and 2 g of cannabis by either vaping, cannabis cigarette, or concentrated wax (dabs) for 10 min. We used standardized laboratory analytical techniques using liquid chromatography-tandem mass spectrometry to analyze both the breath and plasma sample. To analyze the data and find patterns, we developed models using artificial neural network analysis.
Conclusion: Our findings show that tetrahydrocannabinol (THC) breath concentrations peaked in 0.5 hours and reached baseline levels after 2 hours in all the patients. We found an inverse correlation between individuals' body mass index and their peak breath concentrations, and an inverse relationship between age and peak breath concentrations. Male participants had higher peak breath and plasma concentrations than female participants. Our research provides new insight into the correlations between breath and plasma THC concentrations in medical cannabis patients. Copyright 2020, Mary Ann Liebert, Inc., publishers.

Entities:  

Keywords:  breath analysis; clinical trial; medical cannabis; per se legislation; plasma analysis

Year:  2020        PMID: 32322681      PMCID: PMC7173673          DOI: 10.1089/can.2018.0070

Source DB:  PubMed          Journal:  Cannabis Cannabinoid Res        ISSN: 2378-8763


  10 in total

1.  Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis.

Authors:  Nathalie A Desrosiers; Sarah K Himes; Karl B Scheidweiler; Marta Concheiro-Guisan; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2014-02-21       Impact factor: 8.327

2.  Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients.

Authors:  Philippe Lucas; Zach Walsh
Journal:  Int J Drug Policy       Date:  2017-02-09

3.  Detection of drugs of abuse in exhaled breath using a device for rapid collection: comparison with plasma, urine and self-reporting in 47 drug users.

Authors:  Olof Beck; Niclas Stephanson; Sören Sandqvist; Johan Franck
Journal:  J Breath Res       Date:  2013-04-25       Impact factor: 3.262

4.  Exhaled breath for drugs of abuse testing - evaluation in criminal justice settings.

Authors:  Olof Beck
Journal:  Sci Justice       Date:  2013-10-17       Impact factor: 2.124

5.  Smoked cannabis' psychomotor and neurocognitive effects in occasional and frequent smokers.

Authors:  Nathalie A Desrosiers; Johannes G Ramaekers; Emeline Chauchard; David A Gorelick; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2015-03-04       Impact factor: 3.367

6.  Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations.

Authors:  Marilyn A Huestis; Allan Barnes; Michael L Smith
Journal:  Clin Chem       Date:  2005-10-13       Impact factor: 8.327

Review 7.  Cannabis effects on driving skills.

Authors:  Rebecca L Hartman; Marilyn A Huestis
Journal:  Clin Chem       Date:  2012-12-07       Impact factor: 8.327

Review 8.  Rethinking indicators of problematic cannabis use in the era of medical cannabis legalization.

Authors:  Sharon R Sznitman; Robin Room
Journal:  Addict Behav       Date:  2017-09-30       Impact factor: 3.913

9.  Δ(9)-Tetrahydrocannabinol concentrations in exhaled breath and physiological effects following cannabis intake - A pilot study using illicit cannabis.

Authors:  Line Coucke; Enrico Massarini; Zachery Ostijn; Olof Beck; Alain G Verstraete
Journal:  Clin Biochem       Date:  2016-06-08       Impact factor: 3.281

10.  Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis.

Authors:  David M Schwope; Wendy M Bosker; Johannes G Ramaekers; David A Gorelick; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2012-05-15       Impact factor: 3.367

  10 in total
  2 in total

1.  Indeterminacy of cannabis impairment and ∆9-tetrahydrocannabinol (∆9-THC) levels in blood and breath.

Authors:  Gregory T Wurz; Michael W DeGregorio
Journal:  Sci Rep       Date:  2022-05-18       Impact factor: 4.996

2.  A comprehensive breath test that confirms recent use of inhaled cannabis within the impairment window.

Authors:  Michael W DeGregorio; Gregory T Wurz; Edward Montoya; Chiao-Jung Kao
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.